

# Paul E Greenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11812637/publications.pdf>

Version: 2024-02-01

36  
papers

6,799  
citations

304743

22  
h-index

377865

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

8134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry, 2007, 64, 543.	12.3	2,032
2	The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010). Journal of Clinical Psychiatry, 2015, 76, 155-162.	2.2	1,321
3	The Economic Burden of Depression in the United States. Journal of Clinical Psychiatry, 2003, 64, 1465-1475.	2.2	1,104
4	Depression In The Workplace: Effects On Short-Term Disability. Health Affairs, 1999, 18, 163-171.	5.2	323
5	Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depression and Anxiety, 2010, 27, 78-89.	4.1	307
6	The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). Pharmacoeconomics, 2021, 39, 653-665.	3.3	302
7	Workplace performance effects from chronic depression and its treatment. Journal of Health Economics, 1998, 17, 511-535.	2.7	167
8	Depression and Work Productivity: The Comparative Costs of Treatment Versus Nontreatment. Journal of Occupational and Environmental Medicine, 2001, 43, 2-9.	1.7	164
9	The economic burden of depression in the US: societal and patient perspectives. Expert Opinion on Pharmacotherapy, 2005, 6, 369-376.	1.8	135
10	Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001. Clinical Journal of Pain, 2006, 22, 667-676.	1.9	132
11	Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2018, 79, 24-32.	2.2	97
12	Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses. Pharmacoeconomics, 1999, 16, 1-8.	3.3	91
13	Economic Consequences of Not Recognizing Bipolar Disorder Patients. Journal of Clinical Psychiatry, 2003, 64, 1201-1209.	2.2	86
14	Direct and indirect costs of asthma to an employer. Journal of Allergy and Clinical Immunology, 2002, 109, 264-270.	2.9	74
15	Identification of a Claims Data "Signature" and Economic Consequences for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2002, 63, 717-726.	2.2	71
16	Economic Burden of Respiratory Infections in an Employed Population. Chest, 2002, 122, 603-611.	0.8	58
17	Direct and Indirect Costs of Rheumatoid Arthritis to an Employer. Journal of Occupational and Environmental Medicine, 2000, 42, 588-596.	1.7	55
18	Economic Burden of Pneumonia in an Employed Population. Archives of Internal Medicine, 2001, 161, 2725.	3.8	34

#	ARTICLE	IF	CITATIONS
19	Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS ONE, 2019, 14, e0223255.	2.5	32
20	Impact of Illness and Its Treatment on Workplace Costs: Regulatory and Measurement Issues. Journal of Occupational and Environmental Medicine, 2001, 43, 56-63.	1.7	26
21	Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants. Pharmacoeconomics, 2009, 27, 507-517.	3.3	25
22	Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Current Medical Research and Opinion, 2008, 24, 2587-2595.	1.9	23
23	The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opinion on Pharmacotherapy, 2009, 10, 2317-2328.	1.8	21
24	Healthcare resource utilization and costs associated with postpartum depression among commercially insured households. Current Medical Research and Opinion, 2020, 36, 1707-1716.	1.9	20
25	Management of Major Depression in the Workplace. Disease Management and Health Outcomes, 2000, 7, 163-171.	0.4	19
26	Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. Journal of Medical Economics, 2009, 12, 124-135.	2.1	19
27	Medicaid spending burden among beneficiaries with treatment-resistant depression. Journal of Comparative Effectiveness Research, 2019, 8, 381-392.	1.4	18
28	Assessing the Relationship Between Compliance With Antidepressant Therapy and Employer Costs Among Employees in the United States. Journal of Occupational and Environmental Medicine, 2010, 52, 115-124.	1.7	14
29	Cost of depression: current assessment and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2001, 1, 69-76.	1.4	11
30	Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States. Journal of Clinical Psychiatry, 2022, 83, .	2.2	7
31	Does generic substitution always make sense?. Journal of Medical Economics, 2008, 11, 547-553.	2.1	5
32	Antidepressant treatment patterns and costs among US employees. Journal of Medical Economics, 2009, 12, 36-45.	2.1	3
33	Introduction to the Special Issue of Pharmacoeconomics on Major Depressive Disorders. Pharmacoeconomics, 2021, 39, 617.	3.3	1
34	Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. American Health and Drug Benefits, 2011, 4, 78-87.	0.5	1
35	Assessing the economic impact of psychiatric disorders: where to begin?. Expert Opinion on Pharmacotherapy, 2001, 2, 641-652.	1.8	0
36	Cost of Illness: An Ongoing Battle Worth Fighting. Pharmacoeconomics, 2014, 32, 1151-1152.	3.3	0